T4 (Thyroxine) in Human Serum with Roche e801
Detection of Calcium in Human Serum with Roche c502
|Test Name:||In vitro test for the quantitative determination of calcium in human serum and plasma on Roche/Hitachi cobas c systems.|
|Method Name:||Photometrical measurement of the complex formed when calcium ions react with 5-nitro-BAPTA (NM-BAPTA) and EDTA. The change in absorbance is directly proportional to the calcium concentration.|
|Results:||Technical Range: 0.8-20.1 mg/dL
Reportable Range: 1.2-17.88 mg/dL
|Reference Ranges:||<1 year: 8.7-11.0 mg/dL 1-17 years: 9.3-10.6 mg/dL 18-59 years: 8.6-10.0 mg/dL ≥60 years: 8.8-10.2 mg/dL|
|Clinical Significance:||Calcium is the most abundant mineral element in the body with about 99% in the bones primarily as hydroxyapatite. The remaining calcium is distributed between the various tissues and the extracellular fluids where it performs a vital role for many life-sustaining processes. Among the extra skeletal functions of calcium are involvement in blood coagulation, neuromuscular conduction, excitability of skeletal and cardiac muscle, enzyme activation, and the preservation of cell membrane integrity and permeability.
Serum calcium levels and hence the body content are controlled by parathyroid hormone (PTH), calcitonin, and vitamin D. An imbalance in any of these modulators leads to alterations of the body and serum calcium levels. Increases in serum PTH or vitamin D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may be observed e.g., in hypoparathyroidism, nephrosis, and pancreatitis.
|Submission Criteria:||For specimen collection and preparation, only use suitable tubes or collection containers.
Only the specimens listed below were tested and found acceptable.
Plasma: Li-heparin and K2-EDTA plasma
Do not use ammonium heparin
The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, therefore not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.
|Rejection Criteria:||Rejection criteria include but are not limited to:
1. Specimens containing fibrin or clots.
2. Excessive platelet clumping
3. Leaking specimens
4. Substandard mixing or collection
5. Expired or improperly stored collection tubes.
6. Improperly filled tubes based on collection tube manufacturer’s guidelines.
7. Contaminated specimens (IV fluid, foreign particles, etc.)
8. Specimens not analyzed within the appropriate time frame.
9. Samples not shipped at appropriate temperature.
10. Samples without 2 proper identifiers or samples having identifiers that do not match the electronic or paper lab requisition.
|Authorization:||Diagnostic testing can only be performed with approval from an authorized provider/agency.|
|Turn Around Time:||1 day.|